SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of EQRx, Inc. (Nasdaq – EQRX)

BALA CYNWYD – August 1 2023 /NewsFile/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of EQRx, Inc. (“EQRx” or the “Company”) (Nasdaq – EQRX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Revolution Medicines, Inc. (“Revolution Medicines”) (Nasdaq – RVMD). Under the terms of the Agreement, at closing, EQRx stockholders will receive the number of shares of Revolution Medicines stock equal to the sum of ~7.69M Revolution Medicines shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines share price measured in close proximity to the stockholder vote.

The investigation concerns whether the EQRx Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to EQRx shareholders.

If you own shares of EQRx stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.